Wunderkind Joins Klaviyo Marketplace, Bringing Identity-Based Personalization and Revenue Growth to E-Commerce Brands
28.1.2026 15:00:00 CET | Business Wire | Press release
New integration unlocks greater site identification, real-time personalization, and scalable triggered messaging
Wunderkind, the AI decisioning platform that delivers identity resolution and cross-channel personalization to scale performance and reach, today announced its official debut on the Klaviyo App Marketplace.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128210560/en/

The integration brings Wunderkind’s identity insights directly into Klaviyo’s B2C CRM, powering real-time profiles, segments, and flows that help brands recognize more customers earlier in the journey and deliver relevant experiences across email, SMS and other Klaviyo-powered channels.
By layering Wunderkind’s industry-leading Identity Network — built on more than 9 billion device profiles and over a billion unique user identities — into Klaviyo’s unified customer profile, marketers can strengthen their understanding of who customers are, unify identity across channels, and activate personalization through Klaviyo without adding complexity to their tech stack.
“Together, Klaviyo and Wunderkind deliver a future-proof, high-performance solution for brands seeking to maximize the impact, personalization, and efficiency of their messaging programs,” said Richard Jones, Chief Revenue Officer at Wunderkind. “This integration enables brands to activate identity-powered insights directly within Klaviyo, so they can drive smarter decisions, more relevant experiences, and measurable revenue growth — all from a single system of record.”
With Wunderkind now available in the Klaviyo Marketplace, users can:
- Identify more visitors through Wunderkind’s proprietary identity graph, recognizing shoppers across sessions, devices, and brands.
- Grow long-term customer lifetime value through more relevant, consistent experiences delivered through Klaviyo’s native channels.
- Drive incremental revenue through expanded audience reach, higher match rates, and better-timed triggered campaigns.
- Unlock operational efficiency with easy implementation and fast time-to-value.
Brands leveraging Wunderkind’s identity framework have seen up to 8X increases in triggered revenue, while brands using Klaviyo report up to 75% higher lift compared to traditional ESPs when activating personalized, data-driven experiences.
“We’re excited to welcome Wunderkind to the Klaviyo Marketplace,” said Anne Prins, Vice President, Global Product Partnerships at Klaviyo. “This integration gives brands access to identity insights directly within Klaviyo’s real-time customer profiles, helping them recognize more customers, personalize every interaction, and build stronger relationships — all without adding complexity.”
Learn more about the partnership and download the app.
About Wunderkind
Wunderkind is redefining agentic marketing decisioning, where identity meets AI to drive personalized performance at scale. Our Autonomous Marketing Platform (AMP) uses a proprietary identity graph — tracking 9B+ devices and 2T+ digital events annually — to transform anonymous web traffic into known customers, without third-party cookies. AMP dynamically triggers messages across email, text, and ads, optimizing creative, channel, and timing in real time. Seamlessly integrating via SDKs, APIs, and natively with ESPs, it fits any stack without requiring replatforming. Brands like Harley-Davidson and Kendra Scott rely on Wunderkind to unlock reach and revenue, with $5B+ in attributable sales annually and consistently top-ranking channel performance.
About Klaviyo
Klaviyo (NYSE: KVYO) is the B2C CRM. Powered by its built-in data platform and AI insights, Klaviyo combines marketing automation, analytics, and customer service into one unified solution, making it easy for businesses to know their customers and grow faster. Klaviyo (CLAY-vee-oh) helps relationship-driven brands like Mattel, Glossier, Core Power Yoga, Daily Harvest and nearly 200,000 others deliver 1:1 experiences at scale, improve efficiency, and drive revenue.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260128210560/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom